Authors

Joyce O'Shaugnessy, MD, Texas Oncology

Latest:

“HER2 Breast Cancer Talk”: A Review of Data from the SABCS 2020 Virtual Symposium

Joyce Vollmer

Latest:

The Importance of Correct Coding in Specialty-Focused Cancer Treatment Centers

When you consider how complex the system is, and how little training physicians get in medical school about coding, it stands to reason that practice leadership must emphasize its importance.

Ju Dong Yang, MD, MSc

Latest:

Dr. Yang on NASH-Associated HCC and Cirrhosis in Diagnosis of Liver Cancer

Ju Dong Yang, MD, MSc, discusses patients with nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) who present without cirrhosis at the time of diagnosis of liver cancer.

Juan A. Reyna, MD

Latest:

Dr. Reyna on LUGPA Member Ancillary Services

Juan A. Reyna, MD, President, LUGPA, discusses in-office ancillary services among LUGPA members.

Juan Manuel O'Connor, MD

Latest:

Dr. O'Connor Discusses Rationale for CORRELATE Trial in mCRC

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses the rationale for the CORRELATE trial in metastatic colorectal cancer.

Juan P. Alderuccio, MD

Latest:

Dr. Alderuccio on the Use of Proteasome Inhibitors in Frontline Myeloma

Juan P. Alderuccio, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of proteasome inhibitors in the frontline treatment of patients with multiple myeloma.

Juanita Madison, MN, RN

Latest:

Juanita Madison on Handling the Provenge Process

Juanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process

Jubilee Brown, MD

Latest:

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.

Jubilee Brown, MD, Levine Cancer Institute

Judd Moul, MD, Duke Cancer Institute

Judd W. Moul, MD

Latest:

Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

Judd W. Moul, MD, Duke University Medical Center

Judd W. Moul, MD, FACS

Latest:

Dr. Moul on Impact of Obesity in Active Surveillance

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses a recent study that demonstrated the impact of obesity on active surveillance.

Judd W. Moul, MD, FACS, Duke University Medical Center

Judi Payne, BSM

Latest:

Assess, Plan, and Be Flexible for MIPS

Under the new Quality Payment Program, most providers, including community oncologists, are expected to fall under Merit-based Incentive Payment System for the 2017 performance year. With careful analysis and planning, community oncology practices can choose measures that are a good fit and hold the most opportunity for revenue enhancement.

Judith A. Salerno, MD, MS

Latest:

Dr. Salerno on Donations to Breast Cancer Research

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, comments on donations to breast cancer research.

Judith C. McCaffrey, MD

Latest:

Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck Cancers

Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.

Judith K. Wolf, MD

Latest:

Dr. Wolf Discusses the Videssa Breast Blood Test

Judith K. Wolf, MD, chief medical officer of Provista Diagnostics, discusses the capabilities of the blood-based diagnostic test Videssa Breast.

Judith Paice, PhD, RN

Latest:

Paice on Current Pain Management for Breast Cancer

Judith Paice, PhD, RN, director of the Cancer Pain Program, Division of Hematology-Oncology, and research professor of Medicine, Northwestern University, discusses the pain management for patients with breast cancer.

Judith Trotman, MBChB, FRACP

Latest:

Dr. Trotman Discusses Zanubrutinib in Waldenstrom's Macroglobulinemia

Judith Trotman, MBChB, FRACP, FRCPA, clinical professor of medicine, Concord Clinical School, director of Clinical Research Unit, Haematology Department, Concord Hospital, discusses zanubrutinib in patients with Waldenstrom's Macroglobulinemia.